IDXX - IDEXX Laboratories, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

IDXX

IDEXX LABORATORIES, INC.

NASDAQ

$527.07

▲ UP 1.67% (8.68)

KEY STATISTICS

Market Cap$41.58 B

52w High$769.98

52w Low$500.61

Dividend Yield—

Frequency—

P/E37.07

Volume570.11K

Shares Out.78.88M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Michael Erickson

COMPENSATION 2026

Salary$1,150,000

Stock Awards$5,399,881

Incentive Plan Pay$2,593,000

All Other Comp.$37,240

Total$14,580,122

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 21, 1991

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

11,000

PRICE TARGET

Target High$710.00

Target Low$620.00

Target Median$665.00

Target Consensus$665.00

UPCOMING EARNINGS

DateNov 2, 2026

DayMonday

Rev. Est.$1.19B

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2015-06-16	Forward	2:1
2007-11-27	Forward	2:1
1995-06-06	Forward	2:1
1993-10-04	Forward	2:1

ETFS HOLDING THIS STOCK

ETFS HOLDING

1,119

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

62.15%

HOLDERS

1,896

TOP 8 OF 1,896 · RANKED BY POSITION SIZE

Fundsmith Equity Fund, L.P.

Blackrock Fund Advisors

PRICE

$527.07 ▲ UP 1.67% (+$8.68)

OVERLAYS

About IDEXX Laboratories, Inc.

https://www.idexx.com ↗

IDEXX Laboratories develops and distributes veterinary, livestock, water testing, and biomedical diagnostic products and services worldwide, serving veterinary clinics, research, and water quality markets.

INDUSTRY

Medical - Diagnostics & Research

A PRODUCT IDEXX LABORATORIES, INC. IS KNOWN FOR

inVue Dx Cellular Analyzer

The inVue Dx is an in-clinic cellular analyzer that enhances diagnostic accuracy and workflow efficiency for veterinarians, driving rapid adoption and company growth.

COMPETITORS

COMPETITOR

IDEXX Laboratories in 2025

SENTIMENT: + POSITIVE

EARNINGS · AUGUST 4, 2025

IDEXX Laboratories' Stock Soars Over 26% After Smashing Q2 2025 Earnings Expectations and Raising Full-Year Guidance

On August 4, 2025, IDEXX announced exceptional second-quarter financial results that significantly surpassed analyst expectations. The company reported strong revenue growth and a 17% increase in EPS, leading to a substantial single-day stock price surge and prompting an upward revision of its full-year financial guidance.

PRODUCT LAUNCH · MARCH 2025 · COMPLETED

IDEXX Fortifies Diagnostic Leadership with Launch of Advanced Point-of-Care Platforms, Including Breakthrough Cancer and Endocrine Tests

In 2025, IDEXX Laboratories executed a significant product strategy shift by launching multiple innovative diagnostic tests for its point-of-care platforms. Key launches included the IDEXX Cancer Dx™, a novel panel for the early detection of canine lymphoma, and the Catalyst® Cortisol Test for diagnosing endocrine disorders, reinforcing its market leadership and increasing the value of its installed instrument base.

Latest News

BUSINESS WIRE · OCT 1, 2026

IDEXX Laboratories to Release 2026 Third Quarter Financial Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX websi.

READ ARTICLE

EARLIER COVERAGE

PRNEWSWIRE · SEP 30, 2026

Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories

Transaction marks the first realization from the now closed specialist animal health fund's inaugural vehicle CHICAGO, Sept. 30, 2026 /PRNewswire/ -- Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company's acquisition by IDEXX Laboratories, Inc. (NASDAQ: IDXX).

READ ARTICLE